Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HiHat: Sequential Rituximab and Cladribine in RRMS
NCT07517185Phase 2Recruiting
- Sponsor
- Uppsala University
- Start
- Sep 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, cladribine in relapsing-remitting multiple sclerosis (RRMS), sponsored by Uppsala University. Started Sep 2026; status: recruiting.
02
Drugs
rituximabcladribine
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT07517185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07517185.